1. Introduction {#s0005}
===============

Neuroimaging has important research and clinical implications in people with Down syndrome (DS) and Alzheimer\'s disease (AD). Correlating brain changes with clinical presentation can help uncover the mechanisms of dementia development. Clinically, neuroimaging of biomarkers can be used to track the development of AD in DS, allowing for deep phenotyping and analysis of therapeutic efficacy. Furthermore, neuroimaging can be used along with clinical symptoms to help confirm a diagnosis of AD in people with DS. After discussing relevant background information regarding DS and AD, this review provides an overview of clinical neuroimaging studies in the field from the past 10 years. The review is organized by in vivo neuroimaging methods, including ligand-based positron emission tomography (PET), \[18F\] fluorodeoxyglucose (FDG)-PET, structural magnetic resonance imaging (sMRI), diffusion tensor imaging (DTI), electroencephalography (EEG), and retinal imaging. Correlation of imaging changes to cognitive decline is considered, and a discussion of the limitations and feasibility of neuroimaging is included. This review is aimed at clinicians, psychologists, researchers, and those with an interest in DS and/or AD.

2. Background {#s0010}
=============

2.1. Down syndrome overview {#s0015}
---------------------------

In order to appreciate the neuroimaging findings in people with DS and AD, it is important to understand the pathogenesis of DS and its link to AD. DS is a genetic abnormality resulting from an extra copy of chromosome 21, which manifests as intellectual disability and an array of physical characteristics. The vast majority of cases are due to a trisomy of chromosome 21, while 5% are due to Robertsonian Translocation or mosaicism ([@bb0340]). This results in an increased dosage of the gene products on chromosome 21, which can disrupt a variety of pathways, including those involved with brain development, metabolism, and neuronal networks ([@bb0045]). In regards to epidemiology, DS is one of the most common intellectual disabilities, occurring in 1/750 live births ([@bb0015]). The risk of having a child with DS is linked to maternal age, with an 11/1000 chance in women over 40 ([@bb0275]). As our understanding of DS has increased, the lifespan of individuals with DS in developed countries has improved dramatically, as the average person with DS now lives into their 50s ([@bb0360]). With this increase, it is important that we understand the aging process in DS and provide appropriate support throughout the lifespan.

2.2. Structural brain abnormalities in Down syndrome {#s0020}
----------------------------------------------------

Neurodevelopmental abnormalities in DS result in characteristic brain features. People with DS are brachycephalic and have a reduced overall brain size, with a specific reduction in the volume of the frontal and temporal lobes and the cerebellum ([@bb0255]). Within the temporal lobe, the superior temporal gyrus is reduced, while the parahippocampal gyrus can be increased compared to the general population. Recent findings ([@bb0190]) suggest that surface area reductions rather than a decrease in cortical thickness are responsible for the reduced cortical volume in certain areas. Furthermore, structural imaging findings ([@bb0010]) have found that the DS brain has a thicker frontal and occipitoparietal cortex, a thinner motor cortex and temporal pole, a smaller hippocampus and a larger putamen. Additionally, people with DS tend to show accelerated aging in their brains, demonstrating an adjusted brain-predicted age difference increase of 7.69 years ([@bb0080]). It has been demonstrated ([@bb0030]) that the frontal, temporal and parietal lobes show greater age-related reduction than the general population. Understanding these structural differences is important in order to have a framework for how pathologies like dementia alter the DS brain.

2.3. Dementia and Down syndrome {#s0025}
-------------------------------

AD is becoming an important health concern in people living longer with DS. People with DS are at an increased risk of developing dementia compared to the general population, and the onset occurs at a relatively younger age ([@bb0340]). The prevalence of dementia in people with DS is about 3.4% in their 30s, 10.3% in their 40s, and 40% in those over 50 ([@bb0135]). Dementia can be difficult to diagnose in this population for a number of reasons. Individuals with DS may have a low baseline cognitive function, which can negatively affect their performance on cognitive tests designed for the general population that do not take into account the pre-existing intellectual deficits. People with DS also vary considerably in their intellectual ability, and this heterogeneity makes it difficult to establish reliable cut off scores on cognitive tests. For these reasons, DS-specific neuropsychological tests that take into account the spectrum of DS are needed in order to diagnose dementia in this population. In addition to the need for specialized cognitive tests, another challenge in diagnosis is that AD has a different initial presentation in DS compared to the general population, with changes in personality and executive function often manifesting before memory impairment ([@bb0340]). One possible explanation for this is that the frontal lobe in DS is underdeveloped and thus more vulnerable to the effects of amyloid ([@bb0140]), but further research in this area is needed ([@bb0105]). An additional issue in diagnosing AD in people with DS is that they may struggle with communication, so there is often increased reliance on informant reports for diagnosis. Finally, DS is often associated with sensory, neurologic and psychiatric comorbidities which complicate the diagnosis of AD ([@bb0260]). For all these reasons, neuroimaging may be helpful as a complementary method of establishing a diagnosis and monitoring AD in this population.

2.4. Pathogenesis: The amyloid cascade hypothesis and other potential mechanisms {#s0030}
--------------------------------------------------------------------------------

The amyloid cascade hypothesis is a major theory for the development of AD. Amyloid beta (Aβ) is a product of one of the pathways of amyloid precursor protein (APP) proteolysis, where APP is cleaved by beta-secretase 1 and gamma-secretase ([@bb0280]). Aβ peptides can vary slightly in length, and the Aβ42 form is particularly prone to aggregation, arranging into beta sheets that are responsible for amyloid plaques ([@bb0355]). In addition to the fibrillar form, there are also oligomer forms of Aβ42 that may have an even greater detrimental impact on neurons ([@bb0340]). The risk of AD is higher in people with DS compared to people with non-DS intellectual disabilities ([@bb0315]), and this is thought to be due to the presence of APP on human chromosome 21 ([@bb5000]). The trisomy of chromosome 21 in people with DS therefore leads to increased dosage of APP and accumulation of insoluble, neurotoxic Aβ peptides.

Another biomarker for AD is tau, which correlates more closely with cognitive decline ([@bb0350]). Tau is a protein that allows for axonal transport of vesicles and organelles by associating with microtubules ([@bb0340]). In AD, tau can no longer associate with microtubules because it is hyperphosphorylated and, as a result, neurotoxic neurofibrillary tangles (NFTs) are formed. Dual-specificity tyrosine-phosphorylation-regulated kinase 1A is located on chromosome 21, and excess of this kinase in DS could contribute to higher levels of hyperphosphorylated neurotoxic tau ([@bb0210]). On the other hand, animal studies suggest that Aβ pathology drives tau pathology, providing support for the amyloid cascade hypothesis as the key mechanism of AD in DS ([@bb0115]). On a molecular level, some findings suggest that amyloid influences the hyperphosphorylation of tau, promoting the presence of this neurotoxic form ([@bb0095]). Regardless of the principle mechanism of tau pathogenesis, tau clearly plays a key role in neuronal degeneration.

An additional proposed mechanism in AD development is neuroinflammation. Amyloid plaques cause recruitment of microglia and interact with receptors on these cells, leading to production of pro-inflammatory cytokines and reactive oxygen species that are thought to be neurotoxic ([@bb0365]). Because this is a downstream effect of amyloid, involvement of neuroinflammation is consistent with the amyloid cascade hypothesis of AD in DS. However, there is evidence of people with DS showing increased baseline expression of IL-1, an inflammatory cytokine, and chromosome 21 gene product S100B, a protein that is elevated in reactive astrocytes ([@bb0330]). This suggests that neuroinflammation may also be working in parallel with the amyloid cascade to increase predisposition to AD.

In addition to these major theories, there are other genes on chromosome 21 that could play a role in premature brain aging, such as SOD-1 and SLC5A3 ([@bb0030]). Mitochondrial dysfunction in neurons and astrocytes could also be involved, either independently or via altered metabolism of APP ([@bb0055], [@bb0325]). In sum, there are likely several mechanisms happening simultaneously to contribute to AD development in people with DS, but the amyloid cascade hypothesis is the most widely accepted theory for this population. While not all with DS eventually develop AD, these genetic factors certainly place them at risk.

3. Methodology {#s0035}
==============

To ensure that no other reviews exist on this exact topic, a thorough search of Cochrane Library was performed. This review summarizes recent findings from our lab as well as literature on neuroimaging in DS and AD from the past 10 years. To identify articles about neuroimaging in Down syndrome and dementia, a literature search on PUBMED was performed using the keywords Alzheimer\'s disease OR dementia AND MRI AND Down syndrome with the limiters of English, full text, and published in the past 10 years. A MEDLINE search was then performed using the keywords in a different order (Down syndrome AND Alzheimer\'s disease OR dementia AND MRI) with the same limiters. The same steps were taken with the keywords Alzheimer\'s disease OR dementia AND PET AND Down syndrome. Finally, an additional search was made in this way using "neuroimaging" instead of "PET." Sources were also gained from the references of the selected literature. Additionally, the books "Intellectual Disability and Dementia," edited by Karen Watchman, and "Down Syndrome: Current Perspectives," edited by Richard W Newton, Shiela Puri and Liz Marder, were used to gather relevant background information and sources. Articles were chosen for studies that involved DS subjects to assess in vivo neuroimaging changes and their relationship with cognitive decline and dementia status.

4. Results: Neuroimaging trends in Down syndrome with dementia {#s0040}
==============================================================

In this section, we present our findings from our literature review of major neuroimaging studies in the field from the past 10 years. We also discuss studies using emerging modalities such as EEG and retinal imaging.

4.1. PET {#s0045}
--------

We review recent findings using in vivo PET to assess amyloid accumulation in people with DS ([Table 1](#t0005){ref-type="table"}). We also include a discussion of the current amyloid ligands available, and the potential for ligand-based tau studies using PET in this population.Table 1Summary of ligand-based PET findings in DS and AD.Table 1.AuthorsFinal \# of participantsLigand; reference regionResultsScanning feasibility issues[@bb0175]5 with DS/AD, 4 with DS only, 14 healthy controls without DSPiB; CerebellumOnly people with DS older than 45 had significant binding in regions of interest, whether or not they had dementia.1/11 (9.1%) DS participants who agreed to undergo scanning dropped out due to anxiety provoked by elevation of scanning table.[@bb0250]19 with DS, 10 with AD, 10 controls\[18F\]FDDNP; CerebellumHigher binding in DS (in parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus), comparable or higher than AD group in all regions. Binding had positive association with age and behavioural dysfunction in several regions.None reported.[@bb0125]7 with DS and no dementiaPiB; CerebellumThe two subjects with PiB binding showed early striatal accumulation.1/8 (12.5%) participants was unable to complete PET imaging (reason not provided).[@bb0130]63 with DS and no dementiaPiB; Subcortical white matter and cerebellumPositive correlation between binding and age. No relationship between binding and cognitive measures when controlling for age (except for negative correlation with Rivermead Picture Recognition score when binding considered as continuous variable).None for PET. In 9/63 scans (14.3%), T1 MRI failed due to motion artefact; An additional 2/54 (3.7%) did not have T2 acquisition.[@bb0160]39 with DS, 2 of which had dementiaFlorbetaben; CerebellumUptake was correlated with age and was seen in people without AD.None reported.[@bb0285]12 with DS and no dementiaFlorbetapir, CerebellumAmyloid load was associated with hippocampal atrophy. There was an inverse relationship between regional binding and glucose metabolism. No relationship between amyloid load and cognitive measures.None reported.[@bb0305]5 with DS and AD, 12 with DS only, 9 normal controlsFlorbetapir; PonsDS/AD had the highest uptake, followed by DS only. Age-related increases in binding were greater in DS group.1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).[@bb0005]49 with DS (10 of which had dementia and 6 had cognitive decline)PiB; CerebellumBinding begins in striatum around age 40, and was associated with dementia and cognitive decline.None reported (most fell asleep during scan).[@bb0080]46 with DS (9 of which had dementia and 6 with cognitive decline), 30 controlsPiB; CerebellumPiB was associated with brain aging. No relationship between PiB and cognitive score directly, but within the PiB positive group there was a relationship between brain age and cognitive score.None reported.[@bb0180]68 with DS and no dementiaPiB, CerebellumPositive correlation between binding and age, particularly in the striatum.1/72 (1.4%) excluded for being unable to complete PET scan; 1/72 (1.4%) excluded for no TI MRI scan (reasons not provided).[@bb0185]52 with DS and no dementiaPiB; CerebellumBinding occurred first in the striatum, and rate of change in uptake was correlated to pre-existing amyloid. This happened before evidence of dementia or atrophy.None reported.[^1]

### 4.1.1. Amyloid ligands {#s0050}

In order to appreciate PET ligand-based findings, it is important to include a discussion of the current amyloid ligands available. Pittsburgh compound B (PiB) is used to assess amyloid accumulation in AD. PiB specifically binds to amyloid arranged in beta sheets in classic plaques, cerebrovascular amyloid angiopathy, and, to a lesser extent, diffuse plaques ([@bb0075], [@bb0200], [@bb0215]). One limitation of PiB is that it must be manufactured on-site due to its short half-life, and thus fluoride-based compounds can be a useful alternative ([@bb0075], [@bb0300]). While the current amyloid ligands available are useful tools for detecting AD, one drawback is their limited ability to detect non-neuritic amyloid plaques that may occur in a prodromal or early stage of dementia ([@bb0060], [@bb0145], [@bb0155], [@bb0195]). Even among those with late-stage AD, there may be some PiB-refractory cases due to molecular variants of Aβ ([@bb0290]). Thus, it is important to consider these caveats when interpreting in vivo PET results.

### 4.1.2. Amyloid distribution based on PET {#s0055}

It has been known for several decades that Aβ accumulation is nearly universal in people with DS over age 40, as demonstrated by post-mortem studies ([@bb0220]). More recent methods have used PET to visualize Aβ plaques in vivo with radioligands, and this method has been shown to be safe and ethical in people with DS ([@bb0175]). While even those with DS without clinical symptoms of AD show amyloid binding, some of these studies demonstrate that binding is increased with clinically diagnosed dementia status ([@bb0005], [@bb0305]). Findings regarding the relationship between amyloid binding and cognitive performance, however, have been inconsistent ([@bb0005], [@bb0080], [@bb0130], [@bb0250], [@bb0285]). Nonetheless, regardless of cognitive decline or dementia status, it has been consistently demonstrated in PET studies that amyloid increases with age in this population ([@bb0005], [@bb0130], [@bb0160], [@bb0180], [@bb0185], [@bb0250], [@bb0285], [@bb0305]). While causal relationships cannot be determined from these findings, this predisposition of Aβ accumulation prior to dementia onset is consistent with the amyloid cascade hypothesis.

The progression of amyloid accumulation seems to be unique in DS individuals compared to sporadic AD. Recent studies have demonstrated that the first area of accumulation is the striatum ([@bb0005], [@bb0125], [@bb0180], [@bb0185]). [@bb0005] found that amyloid accumulation began in the striatum, starting around age 40, followed by the rostral prefrontal-cingulo-parietal regions, then caudal frontal, rostral temporal, primary sensorimotor and occipital regions, and lastly the mediotemporal regions and remainder of the basal ganglia. This may contrast with amyloid accumulation patterns in sporadic AD in the general population, where an early striatal-only phase has not been demonstrated ([@bb0320]). On the other hand, early striatal binding is seen in familial autosomal dominant AD ([@bb0170]), leading [@bb0005] to hypothesize that this early stage may be unique to amyloid overproduction. Further research on the significance of early striatal binding may help elucidate the mechanism of dementia development in DS individuals.

In sum, PET findings analysing amyloid suggest that amyloid accumulation, beginning in the striatum, is a precursor to the development of dementia. While those with dementia show increased levels of amyloid, there is no clear association between amount of amyloid and performance on cognitive tests. This suggests that while amyloid accumulation may be a necessary step in the progression to dementia, there are likely downstream mechanisms more directly influencing cognitive decline.

### 4.1.3. Tau distribution based on PET {#s0060}

Tau is a microtubule-associated protein that becomes hyperphosphorylated in AD, leading to the formation of NFTs ([@bb0045]). In the general population, tau pathology is a more accurate marker for cognitive decline in AD than amyloid pathology ([@bb0050]). This relationship has been demonstrated in post-mortem pathology of DS brains, correlating NFTs to cognitive decline ([@bb0225]). Certain markers like \[18F\]FDDNP PET have been used to analyse both amyloid plaques and NFTs in this population ([@bb0250]), but there have not been any studies in individuals with DS using PET to analyse tau distribution alone. Future studies in this area may provide valuable insight into the relationship between neuropathological changes and cognitive dysfunction in this population. For example, AV1451 is a tracer increasingly being used to study tau in AD that should prove useful ([@bb0110]). It is possible that in vivo tau imaging will correlate more closely with atrophy and cognitive measures compared to amyloid, providing a missing link between amyloid overproduction and clinically detectable dementia.

### 4.1.4. PET assessment of metabolic activity {#s0065}

FDG-PET is a useful neuroimaging tool in assessing neuronal activity based on glucose metabolism. Changes in FDG have been shown to be associated with cognitive function in people with DS ([@bb0120], [@bb0230], [@bb0285]). Interestingly, even non-demented DS individuals can demonstrate hypometabolism of the posterior cingulate-precuneus, a region that is also hypometabolic in AD in the general population ([@bb0230], [@bb0240]). It has also been demonstrated that those with DS and AD have reduced activity in the posterior cingulate relative to individuals with DS but not AD ([@bb0305]). While the relationship between amyloid accumulation and these metabolic changes is not fully understood, a small pilot study found an inverse relationship between amyloid accumulation and glucose metabolism ([@bb0285]). On the other hand, one study ([@bb0120]) found that some DS participants without clinical signs of dementia demonstrated a higher cerebral glucose metabolic rate in areas of decreased grey matter volume (temporal cortex, hippocampus, thalamus, caudate, and frontal lobe), and that this combination of brain changes in these areas correlated to dementia indicator ratings. It is possible that at an early stage dementia development, metabolic activity is increased in these regions as a compensatory mechanism, similar to some studies in early sporadic AD showing increased metabolism in certain regions ([@bb0040]). Interestingly, the neuronal metabolite profile is also different in DS with dementia relative to DS alone, providing further support that metabolic changes are associated with the development of dementia in this population ([@bb0205]). Thus, FDG PET and metabolite analysis may serve as useful detection tools for dementia. Future studies analysing the chronologic relationship between metabolic changes and cognitive performance would provide important insight on the development of clinical dementia in DS.

4.2. MRI {#s0070}
--------

In this section, we review recent MRI-based findings regarding AD in DS ([Table 2](#t0010){ref-type="table"}). We discuss studies that used sMRI to assess atrophy and studies that used DTI to analyse white matter damage.Table 2Summary of MRI findings in DS and AD.Table 2.AuthorsFinal \# of participantsMethodResultsScanning feasibility issues[@bb0025]19 with DS and AD, 39 with DS onlyT1 MRI with volumetric analysisSmaller hippocampus, caudate, right amygdala and putamen, and greater CSF in people with DS and AD compared to DS alone.None reported.[@bb0270]10 non-demented with DS, 10 with DS and dementia, 10 age-matched controlsFractional anisotropy analysis from DTIPeople with DS have decreased white matter integrity, particularly in the frontal tracts. Cognitive dysfunction is associated with white matter damage. Those with dementia and DS showed increased damage compared to those with DS alone.4 out of 34 (11.8%) initial DS participants excluded due to fear of scan or motion.[@bb0285]12 with DS and no dementiaT1 MRI with volumetric analysisAmyloid load was associated with hippocampal atrophy. Grey matter changes can be detected before clinical dementia onset.None reported.[@bb0305]5 with DS and AD, 12 non-demented with DS, 9 normal controlsT1 MRI with volumetric analysisThose with AD and DS show increased atrophy of the posterior cingulate, parietal, temporal and frontal regions compared to those with DS only.1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).[@bb0230]12 non-demented with DST1 MRI with volumetric analysisMRI can demonstrate a varying degree of AD atrophy in non-demented DS subjects, and this has some correlation with cognitive measures and amyloid burden.1/12 (8.3%) excluded from structural MRI analysis due to blur.[@bb0335]13 PiB negative with DS, 10 PiB positive with DS, 18 controlsFractional anisotropy analysis from DTIThe PiB positive DS group showed decreased white matter integrity, particularly in the posterior tracts, compared to the other groups.Lower IQ or a diagnosis of dementia was correlated with movement artefacts.[@bb0010]46 with DS (19 PiB positive, 27 PiB negative), 30 age-matched controlsT1 MRI with volumetric analysisPosterior-dominant cortical thinning and atrophy of hippocampus, thalamus, and striatum in those with DS and amyloid.3 out of 49 (6.1%) who underwent scanning were excluded due to motion artefact.[@bb0100]45 non-demented with DS, 45 matched controlsFractional anisotropy analysis from DTIPeople with DS have decreased white matter integrity compared to controls, especially in frontal-subcortical circuits, but age-related white matter changes are not accelerated in DS.18 out of 63 (28.6%) who underwent scanning were excluded due to motion artefact.[@bb0185]52 with DS and no dementiaT1 MRI with volumetric analysisAmyloid accumulation occurs prior to dementia onset or grey matter volume reduction.None reported.[^2]

### 4.2.1. Structural MRI {#s0075}

Structural MRI imaging has elucidated the specific brain regions impacted by dementia in DS. These grey matter changes can be detectable before signs of clinical dementia ([@bb0230], [@bb0285]). Nonetheless, grey matter volume reductions seen by sMRI likely occur after amyloid accumulation, as non-demented PiB positive subjects with DS do not always show signs of atrophy ([@bb0185]). Individuals with DS and AD eventually show decreased volume of the hippocampus, amygdala, caudate, posterior cingulate, parietal, temporal, frontal regions and putamen, as well as increased cerebrospinal fluid ([@bb0025], [@bb0305]). It was recently demonstrated that those with DS and amyloid binding show posterior-dominant cortical thinning and atrophy of hippocampus, thalamus, and striatum, which is similar to what is seen in AD in the general population ([@bb0010]). Thus, atrophy seems to be dependent on the presence of amyloid and is exacerbated in those with dementia, consistent with the theory that amyloid may drive atrophy and disease progression.

### 4.2.2. Diffusion tensor imaging for white matter analysis {#s0080}

DTI is an MRI based method to assess the white matter of the brain. Studies have found that those with DS have reduced white matter integrity, especially in the frontal tracts, and that decreased white matter integrity correlates with cognitive dysfunction ([@bb0100], [@bb0270]). People with DS and dementia have been shown to have decreased white matter integrity compared to non-demented DS subjects ([@bb0270]). Another study found increased white matter damage in PiB positive subjects with DS, but this effect was seen predominantly in the posterior tracts ([@bb0335]). This is similar to white matter dysfunction patterns seen in AD in the general population ([@bb0235]). Interestingly, another recent study ([@bb0100]) using DTI suggested that white matter degeneration was not accelerated in non-demented DS subjects relative to normal aging controls. Fenoll et al. suggests this finding could be due to limited sensitivity of DTI in the pre-dementia stage or because accelerated white matter damage may not occur until a later stage in dementia. Due to the limited number of studies and conflicting results, further research using DTI is necessary to determine the relationship between white matter changes and AD in people with DS. It is possible that amyloid accumulation exacerbates white matter damage in an already vulnerable DS brain, but future studies are necessary to explain how this happens mechanistically and relates to clinical symptoms.

4.3. Electroencephalogram (EEG) {#s0085}
-------------------------------

Although not as widely used as PET or MRI, EEG is another potential method of assessing AD in people with DS ([Table 3](#t0015){ref-type="table"}). Even non-demented adults with DS show decreased amplitude of alpha waves, which is similar to what is seen in AD ([@bb0020]). Furthermore, adults with DS and dementia show decreased frequency of theta-1 waves compared to those with DS who do not have dementia ([@bb0310]). Salem et al. also found that theta-1 frequency was negatively correlated with scores on a dementia screening questionnaire, suggesting that increased brain wave abnormality may serve as a marker of dementia progression. Additionally, dementia in DS can be associated with senile myoclonic epilepsy, in which EEG changes may follow a predictable pattern, beginning with diffuse abnormalities during sleep at dementia onset followed by increased risk of myoclonic epilepsy and finally non-epileptic myoclonus as the dementia progresses ([@bb0265]). Future EEG studies in this population may complement other neuroimaging methods in understanding and tracking dementia.Table 3Summary of EEG findings in DS and AD.Table 3:Authors\# of participantsMethodFindings[@bb0020]45 DS subjects, 45 age-matched cognitively normal subjectsEyes-closed resting EEG data collected, with EOG.Central, parietal, occipital, and temporal cortex had alpha and beta rhythms with lower amplitude in DS, while delta rhythms were higher in amplitude in DS.[@bb0265]12 with DS/AD/myoclonic epilepsy, over the age of 40Long-term EEG monitoring during sleep and wake, with EMG and EKG.3 stages of epilepsy were found: diffuse abnormalities during sleep with dementia onset, myoclonic epilepsy, and finally non-epileptic myoclonus with severe dementia.[@bb0310]21 with DS and dementia, 16 with DS and no dementiaEEG during wake resting state, with EOG and EKG.Decreased theta band frequencies in several regions of the brain are correlated with cognitive deterioration based on the Dementia Screening Questionnaire in Intellectual Disability.[^3]

4.4. Retinal imaging {#s0090}
--------------------

Another emerging neuroimaging approach to studying dementia development is retinal imaging via optical coherence tomography (OCT). As the optic nerve shares an embryonic origin with the brain and is part of the central nervous system, the eye is susceptible to the same neurodegenerative pathology such as amyloid plaques. In people with AD in the general population, OCT has shown decreased retinal thickness, and decreased macular volume is correlated with cognitive decline ([@bb0150]). It has also been demonstrated that Aβ accumulation occurs in the lenses of people with DS ([@bb0245]), as well as the retina ([@bb0285]). Similar to PET amyloid studies, it is unclear if there is a direct association between retina amyloid accumulation and cognitive decline in DS ([@bb0285]). Nonetheless, this method is less invasive than MRI and PET, and has the potential to detect AD at an earlier stage ([@bb0035]).

5. Limitations & feasibility of neuroimaging {#s0095}
============================================

Neuroimaging has several limitations and thus should be used in conjunction with cognitive and clinical assessments, as well as other biological measures like plasma amyloid. One issue with neuroimaging is that changes may not be detectable until the disease has progressed significantly. For example, radioligands such as PiB and florbetapir may not be able to adequately detect diffuse Aβ plaques that occur early on in the disease process, potentially limiting their usefulness as prodromal biomarkers. Another issue is that the DS brain has significant differences from typical brains, which is important to keep in mind when considering neuroimaging data. In order to distinguish brain changes due to dementia from anomalies associated with DS, longitudinal studies are needed. Furthermore, it is difficult to assess trends via meta-analysis on neuroimaging results, as the studies are heterogeneous with respect to imaging method, study design, and cognitive performance measure. Finally, neuroimaging is costlier and more time-consuming than other clinical tests, such as psychiatric assessments or plasma amyloid analysis, limiting its feasibility as a widespread diagnostic tool. Nonetheless, the relationship between neuroimaging changes and cognitive function can be highly informative, especially as technology in this field improves.

It is also important to note certain limitations with respect to the studies considered. Many of these studies, particularly those using PET, did not have participants with DS who also had a diagnosis of AD, which limits the conclusions that can be drawn between neuroimaging findings and dementia. This could also suggest a feasibility issue, so it is important to consider the practicality of using neuroimaging in this population for research and clinical purposes. Both low IQ and dementia status have been associated with motion artefacts, and this is particularly important for DTI and functional scans ([@bb0335]). None of the studies discussed used anxiolytics to address this issue, despite the fact that they are sometimes used in the general population prior to scans. There is controversy over the ethicality of using sedatives in the DS population for this purpose, and additionally, these drugs can affect the results obtained from functional scans. The authors of this review therefore recommend establishing a strong relationship with participants and their caregivers and allowing participants the opportunity to familiarise with the process of scanning in order to achieve the best outcomes.

6. Conclusions {#s0100}
==============

Despite certain limitations, these recent neuroimaging findings can help us begin to understand the mechanism of dementia in individuals with DS. Aβ quantification and distribution analysis using PET has revealed a distinct pattern of amyloid accumulation, which may suggest something unique about the pathogenesis of dementia in DS. This accumulation occurs in non-demented individuals with DS and is likely a precursor to the grey matter atrophy and white matter integrity loss seen in later stages of AD. From a clinical perspective, these discoveries can potentially aid our screening and diagnosis of dementia in DS individuals. Monitoring these sequential changes, in conjunction with neurocognitive tests and other biomarkers, may contribute to a more comprehensive clinical picture and allow clinicians to more accurately track dementia progression in this population.

Neuroimaging findings will also have important implications in regards to therapeutics. For example, one implication of this research is the identification of a "therapeutic window" where clinicians can intervene in high risk patients prior to disease progression. As changes detected on certain neuroimaging methods such as ligand-based PET and MRI may occur too late for effective intervention, alternative methods such as retinal imaging, EEG, and FDG-PET may prove particularly useful for this purpose. Early abnormalities detected via these modalities could provide an opportunity to administer potential treatments before the disease manifests clinically. In addition to identifying a therapeutic window, neuroimaging can help inform novel therapeutic targets. This is an area where research is greatly needed, as there are currently no preventative treatments for AD. AD drugs to-date are limited in efficacy and are aimed at treating symptoms rather than the underlying neurodegeneration ([@bb0070]). Finally, another potential application of neuroimaging is to objectively monitor the efficacy of future therapeutics. For all these reasons, neuroimaging and other modalities discussed will likely have a valuable impact on our treatment of AD.

While the clinical utility of this field is evident, there are several areas that require future research. For example, elucidating the relevance of early striatal accumulation to cognitive decline could inform new cognitive screening measures ([@bb0295]). Additionally, as tau correlates more strongly with cognitive decline than Aβ ([@bb0050]), future studies with PET using tau ligand may provide important insight. Tau ligands that have been applied in the general population, such as AV1451 ([@bb0165]), are starting to be utilized for the DS population. Understanding how specific cognitive deficits are related to patterns of tau accumulation may help explain the pathogenesis underlying the unique presentation of dementia in DS. Furthermore, since there has not been a clear association between amyloid distribution and atrophy, it will be useful to determine if tau distribution follows the same pattern as brain atrophy and serves as a link between the two processes. Another important area of future research is the use of neuroimaging to analyse additional markers of AD, such as glial cell markers, in people with DS ([@bb0330]). Finally, future DTI studies may help clarify the impact of amyloid and tau accumulation on the white matter of the DS brain, for example in the striatum. In general, high powered studies that take a prospective longitudinal approach will be critical in increasing our understanding of these mechanisms and identifying biomarkers for tracking dementia development in DS ([@bb0065]). This research will ultimately have great significance for the quality of life of the increasing number of individuals with DS living into their 50′s and beyond, and well as for AD prevention in the general population.
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[^1]: Abbreviations: AD, Alzheimer\'s disease; DS, Down syndrome; FDDNP, 2-(1-{6-\[(2-\[fluorine-18\]fluoroethyl)(methyl)amino\]-2-naphthyl}-ethylidene)malononitrile; PiB, Pittsburgh compound B.

[^2]: Abbreviations: AD, Alzheimer\'s disease; CSF, cerebrospinal fluid; DS, Down syndrome; MRI, magnetic resonance imaging; PiB, Pittsburgh compound B.

[^3]: Abbreviations: AD, Alzheimer\'s disease; DS, Down syndrome; EEG, electroencephalography; EKG, electrocardiography; EMG, electromyography; EOG, electrooculography.
